{"id":87209,"date":"2026-06-26T08:16:31","date_gmt":"2026-06-26T12:16:31","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/european-drug-agency-moves-to-pull-amgens-rare-disease-treatment-from-market\/"},"modified":"2026-06-26T08:16:31","modified_gmt":"2026-06-26T12:16:31","slug":"european-drug-agency-moves-to-pull-amgens-rare-disease-treatment-from-market","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/european-drug-agency-moves-to-pull-amgens-rare-disease-treatment-from-market\/","title":{"rendered":"European Drug Agency Moves to Pull Amgen’s Rare Disease Treatment from Market"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

Europe’s leading medicines authority announced Friday that it is recommending the removal of Amgen’s drug Tavneos from the market, determining that the treatment’s potential benefits do not justify the risks it poses to patients.<\/p>

The European Medicines Agency made the recommendation after concerns about the drug’s safety profile mounted. Earlier, in April, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research had already proposed pulling its own approval of Tavneos, following the identification of 76 cases of drug-induced liver injury \u2014 with evidence pointing to the drug as the likely cause.<\/p>

Tavneos is used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis, an uncommon category of autoimmune disorders that trigger dangerous inflammation in small- to medium-sized blood vessels throughout the body.<\/p>

The EMA’s Committee for Medicinal Products for Human Use issued guidance stating that no new patients should begin taking Tavneos. For those already on the medication, the committee recommends transitioning to appropriate alternative therapies.<\/p>","protected":false},"excerpt":{"rendered":"

Europe’s top medicines regulator has recommended pulling Amgen’s rare autoimmune disease drug Tavneos from the market, saying its risks outweigh its benefits. The move follows a similar action by U.S. regulators earlier this year, who flagged dozens of cases of serious liver injury linked to the drug. Patients currently on the medication are being advised to switch to other treatment options.<\/p>\n","protected":false},"author":4,"featured_media":87208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[837],"tags":[],"class_list":["post-87209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1782476191077.jpg?fit=450%2C316&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-mGB","jetpack-related-posts":[{"id":55775,"url":"https:\/\/tvdelmarva.com\/wp\/eu-drug-chief-warns-europe-faces-crisis-in-access-to-new-medications\/","url_meta":{"origin":87209,"position":0},"title":"EU Drug Chief Warns Europe Faces Crisis in Access to New Medications","author":"Admin","date":"April 22, 2026","format":false,"excerpt":"The head of Europe's drug regulatory agency warns the continent faces a crucial moment for securing access to new medications as U.S. pricing policies disrupt the pharmaceutical industry. Drug launches in Europe have dropped by over one-third since new American pricing rules took effect last year.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776867765828.jpg?fit=450%2C299&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":65201,"url":"https:\/\/tvdelmarva.com\/wp\/european-union-agrees-on-plan-to-boost-medicine-production-cut-foreign-dependence\/","url_meta":{"origin":87209,"position":1},"title":"European Union Agrees on Plan to Boost Medicine Production, Cut Foreign Dependence","author":"Admin","date":"May 12, 2026","format":false,"excerpt":"European lawmakers reached a preliminary agreement Tuesday to strengthen the continent's pharmaceutical supply chain by boosting domestic production of critical medications. The deal aims to reduce Europe's reliance on foreign countries for essential drugs like antibiotics, insulin and vaccines.","rel":"","context":"In "World News"","block_context":{"text":"World News","link":"https:\/\/tvdelmarva.com\/wp\/category\/world-news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778570642598.jpg?fit=450%2C295&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":68724,"url":"https:\/\/tvdelmarva.com\/wp\/swedish-biotech-secures-134m-european-licensing-deal-for-kidney-drug\/","url_meta":{"origin":87209,"position":2},"title":"Swedish Biotech Secures $134M European Licensing Deal for Kidney Drug","author":"Admin","date":"May 19, 2026","format":false,"excerpt":"Hansa Biopharma announced a major licensing agreement worth up to $134 million with SERB Pharmaceuticals for its kidney transplant medication Idefirix across European markets. The deal strengthens the Swedish company's financial position ahead of a potential U.S. drug approval decision expected in December.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":80005,"url":"https:\/\/tvdelmarva.com\/wp\/japanese-pharmas-ai-developed-psoriasis-drug-beats-competitor-in-major-trial\/","url_meta":{"origin":87209,"position":3},"title":"Japanese Pharma’s AI-Developed Psoriasis Drug Beats Competitor in Major Trial","author":"Admin","date":"June 11, 2026","format":false,"excerpt":"A Japanese pharmaceutical company announced Thursday that its experimental psoriasis medication, created with artificial intelligence assistance, showed superior results compared to an existing treatment in clinical trials. The once-daily pill achieved complete skin clearance in 35% of patients after 16 weeks, more than double the rate of the competing drug.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781183249773.jpg?fit=450%2C312&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":78870,"url":"https:\/\/tvdelmarva.com\/wp\/synthetic-opioids-pose-growing-threat-across-europe-drug-agency-reports\/","url_meta":{"origin":87209,"position":4},"title":"Synthetic Opioids Pose Growing Threat Across Europe, Drug Agency Reports","author":"Admin","date":"June 9, 2026","format":false,"excerpt":"The European Union's drug monitoring agency warns that synthetic opioids are becoming an increasing concern across the continent as illegal drug markets continue to evolve. While Europe still sees significantly fewer overdose deaths than North America, officials identified at least 50 new psychoactive substances in 2025.","rel":"","context":"In "World News"","block_context":{"text":"World News","link":"https:\/\/tvdelmarva.com\/wp\/category\/world-news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781011353129.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781011353129.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781011353129.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781011353129.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781011353129.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":41764,"url":"https:\/\/tvdelmarva.com\/wp\/cancer-drug-shortage-expected-to-continue-through-early-2025-in-europe\/","url_meta":{"origin":87209,"position":5},"title":"Cancer Drug Shortage Expected to Continue Through Early 2025 in Europe","author":"Admin","date":"March 24, 2026","format":false,"excerpt":"European health officials warn that a critical cancer medication shortage will persist into early 2025 due to manufacturing problems at Baxter International. The drug ifosfamide is used to treat testicular, cervical, and small cell cancers across the European Union.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774363871520.jpg?fit=450%2C299&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/87209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=87209"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/87209\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/87208"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=87209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=87209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=87209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}